alnylam
The Associate Director, Antibody Development at Alnylam leads the CMC strategy and execution for antibody and antibody-conjugate programs, overseeing cell line development, upstream and downstream process development, and working with internal teams and external vendors to ensure program milestones and regulatory readiness.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
22% above the average for this role
Director, CMC – Biologics & ADC
Pathos
Senior Scientist I (Protein & Antibody Production)
Exelixis
Senior Principal Scientist - Process Development
Lonza
MSAT Engineer/ Senior Engineer - Temporary/ Full-time
Brinova Fastigheter AB
Director or Senior Director, CMC Protein Biologics
Scripps Research
Executive Director, Process Development & Manufacturing
Janux Therapeutics